- 肿瘤药物治疗方案及综合评价
- 李秋 张晓实主编
- 144字
- 2022-04-21 16:38:11
方案Ⅱ 凡德他尼
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T30_292_808_2020_1047_77603.jpg?sign=1739253626-1osjDFgjkwhhsVAaTgqnoniB8m87og9A-0-2ab2ebc71ccd9134ea122a6a0f686080)
方案评价
![](https://epubservercos.yuewen.com/B8A9D8/22919013101368106/epubprivate/OEBPS/Images/T30_287_1133_2052_2775_147304.jpg?sign=1739253626-G8rETfnvFGLRxPOwARwsa4lAfSAdJMM6-0-214a7a2d57e3c0345dc3aeb50ee55b02)
点评
凡德他尼是局部进展、转移性甲状腺髓样癌的优选方案。证据来源于Ⅲ期随机对照研究,适用于PS评分0~2,血钙≥500pg/ml、有可测量病灶、不可手术切除的局部进展、转移性甲状腺髓样癌。
(吴 昕 张琼文)
参考文献
[1] WELLS SA JR,ROBINSON BG,GAGEL RF,et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized,double-blind phase Ⅲ trial.J Clin Oncol,2012,30:134-141.